Amazon's Strategic Surge: From Orbit to AI Labs, a Dual-Pronged Offensive

Amazon's stock surged 4% on a dual strategy: acquiring Globalstar for satellite dominance and launching a new AI platform for drug discovery, backed by massive AWS investment.

Amazon's stock climbed nearly 4% to €211.20 on Tuesday, fueled by a pair of strategic moves that underscore the company's ambition to dominate both the skies and the frontiers of artificial intelligence. The rally brings the share price within striking distance of its 52-week high of €220.55.

In a bold expansion of its satellite venture, Project Kuiper, Amazon announced the acquisition of satellite operator Globalstar for $11.6 billion. Shareholders are being offered $90 per share in cash or Amazon stock, a premium of approximately 117% over Globalstar's late-October price. With about 58% of voting rights already in favor, the deal is slated for completion in 2027. Beyond the hardware, the acquisition's true value lies in Globalstar's globally harmonized L-band and S-band frequency licenses across more than 120 countries—critical assets for providing direct-to-device connectivity from satellites to standard smartphones.

This satellite push comes with a flagship partner already secured. Amazon and Apple have inked a deal for Amazon to provide future satellite services for iPhone and Apple Watch, including the Emergency SOS via Satellite feature. Apple, which had previously invested around $1.5 billion in Globalstar, ensures continuity for its safety services while planning new features like satellite-powered Apple Maps and messaging. The acquisition gives Amazon control over the infrastructure upgrades needed to make these services a reality.

Simultaneously, Amazon's cloud division, AWS, is making significant inroads into the life sciences sector with the launch of "Amazon Bio Discovery." This platform provides researchers access to over 40 specialized AI models designed to drastically accelerate drug discovery, integrating directly with DNA synthesis firms like Twist Bioscience. Early customers include Bayer and the Broad Institute. AWS revealed its AI services are now generating an annual revenue run rate exceeding $15 billion, a figure driven in part by its custom Graviton and Trainium chips, which themselves boast a run rate of over $20 billion.

To support this explosive growth, Amazon is undertaking a historic infrastructure build-out. The company plans record capital expenditures of roughly $200 billion for 2026, with the majority flowing into AWS. A single project in Mississippi represents a $25 billion investment in new data centers. The cloud giant also solidified its position in the enterprise AI market through a landmark partnership with OpenAI, involving investments of up to $50 billion. Under the agreement, AWS becomes the exclusive third-party provider for OpenAI Frontier, while OpenAI commits to using massive amounts of Amazon's Trainium chip capacity.

Wall Street remains bullish on Amazon's aggressive strategy. Analysts from Goldman Sachs, Evercore ISI, and Stifel Nicolaus reaffirmed Buy ratings with price targets ranging from $275 to $294. Roth Capital also maintained its Buy recommendation with a $285 target following the Globalstar news. For the current first quarter of 2026, Amazon has guided for an operating income between $16.5 and $21.5 billion. The coming weeks will test whether sustained demand for AWS's new services and the strategic clarity of its satellite acquisition can propel the stock past its recent peak.